Study #2024-0481
A phase 1/2 study to evaluate the safety and efficacy of MK-2870 monotherapy or in combination with other anticancer agents in gastrointestinal cancers
MD Anderson Study Status
Enrolling
Treatment Agent
Sacituzumab tirumotecan, Fluorouracil (5-FU), Leucovorin (LV) or levoleucovorin, Rescue medication, Supportive care measures
Description
Researchers want to learn if sacituzumab tirumotecan (MK-2870) alone or with chemotherapy can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are either advanced (the cancer has spread to other parts of the body), or unresectable (the cancer cannot be removed with surgery). The goals of this study are to learn: * About the safety and how well people tolerate sacituzumab tirumotecan alone or with chemotherapy * How many people have the cancer respond (get smaller or go away) to treatment
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer
Study phase:
Physician name:
Kanwal Raghav
Department:
Gastrointestinal Medical Oncology
For general questions about clinical trials:
1-844-539-2756
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.